Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease
- PMID: 32839034
- DOI: 10.1016/j.jhep.2020.06.003
Blood biomarkers for the diagnosis of hepatic steatosis in metabolic dysfunction-associated fatty liver disease
Conflict of interest statement
Conflict of interest The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: Correspondence on "A new definition for metabolic associated fatty liver disease: an international expert consensus statement": MAFLD: Moving from a concept to practice.J Hepatol. 2020 Nov;73(5):1268-1269. doi: 10.1016/j.jhep.2020.06.036. Epub 2020 Aug 13. J Hepatol. 2020. PMID: 32800588 No abstract available.
Comment on
-
A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement.J Hepatol. 2020 Jul;73(1):202-209. doi: 10.1016/j.jhep.2020.03.039. Epub 2020 Apr 8. J Hepatol. 2020. PMID: 32278004 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
